Polypeptides comprising Fas activation and NKG2D-ligand domains
View Patent ↗The present invention is drawn to fusion proteins comprising (a) a ligand for an NK receptor and (b) a Fas activation domain, and to nucleic acids encoding such fusion proteins. The invention also includes methods of making and using such proteins and nucleic acids, including their use in preventing or treating cancer.
1. A polypeptide comprising (i) a ligand for a stimulatory Natural Killer (NK) receptor and (ii) an intracytoplasmic death domain (DD), wherein the ligand for a stimulatory NK cell receptor comprises the extracellular domain of MULT-1.
2. A polypeptide comprising (i) a ligand for a stimulatory Natural Killer (NK) receptor and (ii) an intracytoplasmic death domain (DD), wherein the ligand for a stimulatory NK cell receptor comprises the amino acid sequence of amino acids 1 to 211 of SEQ ID NO:1.
3. The polypeptide of claim 2 , wherein the ligand for a stimulatory NK cell receptor comprises the amino acid sequence of SEQ ID NO:1.
4. A polypeptide comprising (i) a ligand for a stimulatory Natural Killer (NK) receptor and (ii) an intracytoplasmic death domain (DD), wherein the DD comprises the amino acid sequence of amino acids 166 to 327 of SEQ ID NO:2.
5. A polypeptide comprising (i) a ligand for a stimulatory Natural Killer (NK) receptor and (ii) an intracytoplasmic death domain (DD), wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:3.